Attachment II - Page 4 
93«3-038 
9303-039 
9303-040 
9303-041 
9303-042* 
9306-043 
9306-044* 
9306-045 
9306-046 
9306-047 
9306-048 
93064)49 
9306- EXP 
93064)50 
(M) Heslop, Hckn E.; Breaner, Malcolm K.; tad Rconey, Qioaa, St Jud« Childien’s Research Hospital, Memphis, Tennessee; 
Adndr^ttraiion of Neomycin RetUuoice Gene Marked £fiV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or 
PhenotypicaUy Similar Unrelated Donor Marrow Grqfts. 
RAC ApprtTval: 3-2-93/NIH Approval: 4-16-93 
(M) Brenner, Malcolm K.; Krance, Robert; Heslop, Helen E.; Santana, Victor; and Ihle, James, St Jude Children’s Research Hospital, 
Memphis, Tennessee; Assessment of the Efficacy of Purging by Using Gene-Marked Autologous Marrow Transplantation for Children 
with Acute Myelogenous Leukemia in First Complete Remission, 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
(T^ Simons, Jonathan, Johns Hopkins Oncology Center, Baltimore, Maryland; Phase I Study of Non-Replicating Autologous Tumor Cell 
Injections Using Cells Prepared With or Without Granulocyte-Macrophage Colony Stimulating Factor Gene Transduction in Patients with 
Metastatic Renal Cell Carcinoma. 
RAC Approval: 3-1-93/NIH Approval: 12-2-93 
(T) Wilmott, Robert W. and Whitsett, Jeffrey, Quldren’s Hospital Medical Center, Cincinnati, Ohio, and Trapnell, Bruce; Genetic 
Therapy, Inc, Gaithersburg, Maryland; A Phase I Study of Gene Therapy of Cystic Fibrosis Utilizing a Replication Deficient 
Recombinant Adenovirus Vector to Deliver the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Airways. 
RAC Approval: 3-2-93/NIH Approval: 4-16-93 
(T) Boucher, Richard C and Knowles, Michael R, University of North Carolina, Chapel Hill, North Carolina; Gene Therapy for Cystic 
Fibrosis Using El Deleted Adenovirus: A Phase I Trial in the Nasal Cavity. 
RAC Approval: 3-2-93/NIH Approval: 10-7-93 
Minor Modificatioo: 2-17-94 
(T) Seigler, Hilliard F, Duke University Medical Center, Durham, North Carolina; A Phase I Trial of Human Gamma Interferon- 
Transduced Autologous Tumor Cells In Patients With Dissemiruited Malignant Melanoma. 
RAC Approval: 6-7-93/NIH Approval: 9-3-93 
(T) Deisseroth, Albert B.; Kavanagh, John; and Champlin, Richard, University of Texas MD Anderson Cancer Center, Houston, Texas; 
Use of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for 
Chemoprotection During the Therapy of Ovarian Cancer: A Pilot TriaL 
RAC Approval: 6-7-93/NIH Approval: 12-2-93 
Minor Modificatioo: 2-25-94 
Minor Modification: 2-2S-94 
(T) Nabel, Gary J, University of Michigan Medical Center, Ann Arbor, Michigan; Immunotherapy for Cancer by Direct Gene Transfer 
into Tumors. 
RAC Approval: 6-7-93/NIH Approval; 9-3-93 
(T) Barranger, John A, University of Pittsburgh, Pittsburgh, Pennsylvania, Gene Therapy for Gaucher Disease: Ex Vivo Gene Transfer 
and Autologous Transplantation of CD34(-k) Cells. 
RAC Approval: 6-7-93/NIH Approval: 9-3-93 
(T) Karlssoo, Stefan and Dunbar, Cynthia, National Institutes of Health, Bethesda, Maryland, and Kohn, Donald B, Childrens Hospital 
Los Angeles, Los Angeles, California; Retroviral Mediated Transfer of the cDNA for Human Giucocerebrosidase into Hematopoietic 
Stem Cells of Patients with Gaucher Disease. 
RAC Approval: 6-7-93/NIH Approval: 9-3-93 
(T) Galpin, Jeffrey E., University of Southern California, and Casciato, Dennis A, University of California, Los Angeles, California; A 
Preliminary Study to Evaluate the Safety and Biologic Effects of Murine Retroviral Vector Encoding HTV-l Genes [HIV-rT(V)] in 
Asymptomatic Subjects Infected with HTV-l. 
RAC Approval: 6-7-93/NlH Approval: 9-3-93 
(T) Nabel, Gary J, University of Michigan Medical Center, Ann Arbor, Michigan; A Molecular Genetic Irttervention for AIDS - Effects of 
a Transdominant Negative Form of Rev. 
RAC Approval: 6-7-93/NIH Approval: 9-3-93 
(T) Sobol, Robert and Royston, Ivor, San Diego Regional Cancer Center, San Diego, California; CONFIDENTIAL, 
NIH Approval: 12-28-92 
Major Amendment (Expedited Review)/NIH Approval: 5-11-93 
(T) Raffel, Corey, Childrens Hospital Los Angeles, Los Angeles, California, and Culver, Kenneth, Iowa Methodist Medical Center, Des 
Moines, Iowa; Gene Therapy for the Treatment of Recurreru Pediatric Malignant Astrocytomas with In Vivo Tumor Transduction with the 
Herpes Simplex Thymidine Kinase Gene. 
RAC Approval: 6-8-93/NlH Approval: 9-3-93 
Recombinant DNA Research, Volume 19 
[751 
